GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...
GSK PLC licensor Hansoh Pharmaceutical Group Co. Ltd., announced positive overall survival (OS) data from ARTEMIS-008, its pivotal phase III trial in China evaluating the B7-H3-targeted antibody-drug ...
MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel ...
GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.
GSK (GSK) said Monday clinical trial data showed its drug zidesamtinib achieved a 94% response rate in patients with advanced lung cancer who had not received prior targeted therapy. All trial ...
On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...
Pharmaceutical company GlaxoSmithKline is using mobile health tools in a small study -- just six subjects -- that could lead to there more widespread use in clinical trials. The company is working ...
Under fire from industry critics, UK drug manufacturing giant GlakoSmithKline has announced its intent to publish clinical trials data-a first for both the company and the pharmaceutical industry, ...
The MarketWatch News Department was not involved in the creation of this content. -- Pi Health to use its proprietary technology platform to provide end-to-end global clinical research services in a ...
Pharmaceutical manufacturer GlaxoSmithKline is making waves for the second time in the last four months, announcing that in response to a new clinical trials data transparency initiative, it will ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...